Calix Limited Overview
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Employees (approx, third-party data) | 155 | 130 | 108 |
Note: The FY2024 figure is from Yahoo Finance and FY2026 from Investing.com/S&P. FY2025 (130) is an interpolated placeholder and is not publicly disclosed. Treat the trend as directional only: headcount fell after FY25 restructuring (redundancy payments of A$1.0m in 1H FY25 and A$0.4m in 1H FY26, per Interim Report Note 5).
Calix Limited is an Australian industrial-technology company built around a patented electrically capable, indirectly heated flash-calcination kiln. The kiln separates process CO2 from combustion gases, accepts fine feedstocks and can run on electricity, conventional fuels or hybrids. Commercially, Calix is a two-speed business. Its cash engine is Magnesia: magnesium oxide and hydroxide products for wastewater treatment and aquaculture, made at Bacchus Marsh (Victoria) and sold mainly in North America through subsidiary Inland Environmental Resources. Magnesia delivered A$34.0m of revenue in FY26, up 40%. Around it sits a portfolio of pre-commercial licensing platforms: Leilac (cement and lime carbon capture), Zesty (hydrogen direct-reduced green iron), alumina electrification with Norsk Hydro, lithium mid-stream processing licensed to PLS, and carbon-dioxide removal. In FY26 Calix pivoted to a "capital-light, customer-funded" model after a A$30.2m impairment and Leilac-2 delays. The investment case is a profitable-niche magnesia business plus option value on industrial decarbonisation licensing, constrained by a thin cash position.
Company's own description
In its FY26 results release, Calix calls itself "an industrial technology company transforming the way the world's essential materials are made". It says its patented platform technology is designed to "enable flexible energy use and electric heating, more efficient resource use, and the capture of unavoidable carbon dioxide emissions". It names its target markets as "cement and lime to iron and steel, alumina, critical minerals, water treatment and carbon dioxide removal". (Source: FY26 Results announcement, 26 Aug 2026.)
The 1H FY26 Interim Report lists six claimed technology benefits:
-
Energy optionality (electricity, conventional or alternative fuels).
-
Flexible electrification compatible with variable renewables and grid balancing.
-
Capture of unavoidable process CO2 uncontaminated by combustion gases.
-
Value-added processing of fines and dust at the mine site.
-
Minimal hydrogen use in reduction reactions (hydrogen used only as reductant and recyclable).
-
Highly active, high-surface-area materials from flash heating.
Business model and revenue model
| Revenue stream | Description | Weight (FY26) |
|---|---|---|
| Product sales (Magnesia) | MgO/Mg(OH)2 slurries and powders for wastewater, biogas, aquaculture; sold under contract and repeat order | ~94% of product & services revenue (A$34.0m of A$36.0m) |
| Rental revenue | Equipment rental agreements, mostly Magnesia dosing assets | <2% (A$0.26m in 1H FY26) |
| Engineering / technical services | Paid studies, pre-FEED, material testing (Leilac, Hydro, East Asia cement, Frontier) | ~A$2.0m combined Leilac + SusPro in FY26 (derived) |
| Licensing / royalties | Head licensor of Calix technology; retains 30% of Leilac Group royalties regardless of equity; 20% share of third-party lithium royalties (PLS) | Nil material to date |
| Grants and incentives (other income) | ARENA, EU Horizon 2020, Australian Government, UK R&D tax incentives | Recorded as other income (A$1.3m in 1H FY26) |
Calix runs a hybrid product-plus-licensing model:
The stated long-term model is "capital-light licensing". Calix develops and demonstrates the technology with partners and grant funding, then licenses it to industrial majors, who fund commercial plants. The 19 Feb 2026 PLS announcement describes the lithium restructure as realigning commercialisation with "Calix's long-term capital-light licensing model".
Value-chain position
Magnesia: Vertically integrated. Calix owns a magnesite (magnesium carbonate) mine at Myrtle Springs, South Australia, calcines at Bacchus Marsh, hydrates in Victoria and Queensland, and runs six North American manufacturing/slurry facilities with direct customer delivery.
Decarbonisation platforms: Technology developer and licensor at the process-equipment and IP layer. It sits upstream of cement, lime, steel, alumina and lithium producers, and alongside EPC firms and equipment OEMs.
Customer types and end markets
| End market | Customer types | Status |
|---|---|---|
| Industrial and municipal wastewater (US, Australia) | Food processors, industrial plants, municipal utilities | Commercial, growing |
| Aquaculture / lake remediation | Shrimp farmers, water managers | Commercial (smaller) |
| Cement and lime | Heidelberg Materials, Ambuja Cements (Adani), confidential East Asian producer, Titan America, MLC (paused) | Pilot / paid engineering |
| Iron and steel | Rio Tinto (JDA); Australian Government (ARENA) | Demonstration (pre-FID) |
| Alumina | Norsk Hydro (Alunorte refinery, Brazil) | Paid pilot testing done Jun 2026 |
| Lithium | PLS Group (formerly Pilbara Minerals) | Demo plant commissioning; licensed |
| Carbon dioxide removal | Frontier buyers (Google, Stripe, Shopify); DAC (Heirloom exclusivity removed) | Paid R&D |
Independent characterisation
On FY26 numbers, Calix is economically a ~A$36m-revenue North American wastewater-chemicals business attached to an R&D-heavy decarbonisation venture portfolio. The Magnesia segment has turned profitable at the segment level (1H FY26 segment net profit A$0.6m versus a A$1.9m loss in 1H FY25). Group losses come from Leilac, Sustainable Processing and corporate overhead.
Over FY23–FY25 the company tried to fund demonstration plants directly (Leilac-2, the lithium Mid-Stream UJV). That strategy ended with a A$30.2m write-down of the lithium UJV in 1H FY26 and the de-prioritisation of Leilac-2 in June 2026. The equity market has re-rated the stock accordingly: the price fell from ~A$1.77 (52-week high, early 2026) to A$0.225 by October 2026.
Strategy
Stated strategy (themes from FY26 results and investor communications)
-
"Capital-light, customer-funded" commercialisation. In the CEO's words, FY26 "marked a shift in Calix's strategy, with a focus on applications that can improve industrial competitiveness today while enabling lower-emissions production over time—prioritising capital-light, customer funded projects."
-
Grow Magnesia "with a focus on customer service, operational reliability, safety and disciplined expansion" (FY27 priority 1).
-
Paid test campaigns and customer-funded development in Sustainable Processing (FY27 priority 2).
-
Advance financing and FID for the Zesty Demonstration Plant (FY27 priority 3), with A$3m of the A$11.4m PLS proceeds reinvested to accelerate Zesty.
-
Commercialise Leilac through capital-light pathways, prioritising customer-funded projects and partnerships for commercial-scale demonstration (FY27 priority 4).
-
Platform licensing. Calix acts as head licensor; partners (Rio Tinto, Hydro, PLS, Adani, Heidelberg) fund deployment.
-
Positioning shift: from "environmental technology" (2025) to "industrial technology" (2026). The FY26 messaging stresses competitiveness (energy-cost savings, hybrid electrification, capacity uplift) alongside decarbonisation, reflecting weaker carbon-policy tailwinds, particularly in the US.
Strategic initiatives (last 24 months)
| Initiative | Date | Description | Status |
|---|---|---|---|
| FY25 cost-reduction programme | FY25 | Discontinue non-priority activities, streamline teams; operating cost base down 23% in 2H vs 1H FY25; ~A$8m annualised savings | Delivered; FY26 opex -24% |
| Capex reduction | FY26 | Cash capex down 80% to A$2.1m | Delivered |
| Lithium Mid-Stream restructure | Feb–Jul 2026 | Exit UJV for A$11.4m; perpetual licence to PLS; 20:80 third-party royalty split | Completed (both payments received) |
| Zesty green iron demo | Jul 2025 onward | ARENA up to A$44.9m; Rio Tinto JDA >A$35m; Kwinana site | Detailed design; FID targeted FY27 |
| Alumina electrification (Hydro) | Sep 2025 onward | Testing plus pre-FEED >A$1.0m revenue | Pilot testing completed Jun 2026 |
| Leilac portfolio reprioritisation | 29 Jun 2026 | Focus on Ambuja, East Asia and Frontier; de-prioritise Leilac-2, ZETA, US projects | Implemented |
| Leilac–Ambuja commercial project | 23 Jun 2026 | JDA, customer-funded capex | Engineering phase |
| Frontier CDR lime | 22 Jan 2026 | Zero-emissions lime for ocean alkalinity enhancement | Paid phase due 1H FY27 |
| DAC open licensing | Jun 2026 | Heirloom exclusivity removed | Seeking new partners |
| Banking facility | Feb 2026 | Bank of America facility replacing Columbia Bank line (IER) | Executed |
| US Magnesia expansion | Dec 2025 | Contract worth up to A$10m a year | Deliveries from Jan 2026 |
Guidance and medium-term targets
| Guidance item | Detail | Source |
|---|---|---|
| Cash flow | Expects to be cash-flow neutral in CY2026, excluding A$11.4m PLS proceeds | FY26 results; 1H FY26 results |
| Revenue | Continued revenue and gross-profit growth in Magnesia (no numerical target) | FY26 results |
| Zesty | Advance financing and FID | FY26 results |
| Capex | Minimal; limited to what Magnesia growth requires (going-concern assumptions) | 1H FY26 Interim Report |
| Quantitative medium-term targets (revenue, EBITDA, margin) | — | — |
Sustainability commitments
Calix's purpose-led messaging ("Because there's only one Earth. Mars is for quitters.") positions the company's products as decarbonisation enablers.
Products & Services
Magnesia segment
| Product / service | Description and capabilities | Target customer | Launch / status | Pricing model |
|---|---|---|---|---|
| ACTI-Mag (magnesium hydroxide liquid/slurry) | Highly active Mg(OH)2 slurry from flash-calcined MgO; raises alkalinity and pH, controls odour/H2S and corrosion, replaces caustic soda in wastewater and biogas | Municipal utilities, food and beverage processors, industrial wastewater, wineries | Commercial for over 10 years; scaled in US via IER from Dec 2019 | Per-tonne supply contracts and long-term repeat orders; some equipment rental |
| Magnesium Hydroxide Liquid (MHL) — IER brand | US distribution and manufacture of MHL through six North American facilities | Pacific Northwest and Midwest US industrial and municipal customers (80+ at acquisition) | Acquired Dec 2019 | Supply contracts; new contract with a US customer worth up to A$10m a year (Dec 2025) |
| AQUA-Cal+ | Water and pond conditioner for prawn/shrimp aquaculture and lake remediation | Aquaculture farms, lake managers | Commercial (smaller volume) | Product sales |
| Magnesium oxide powders | Calcined MgO from Bacchus Marsh (up to 25,000 tpa) | Hydration plants (internal), industrial users | Commercial | Product sales |
| Dosing and application assets (rental) | Slurry manufacturing and application equipment at customer sites (A$13.8m gross "slurry manufacturing and application assets") | Wastewater customers | Ongoing | Rental agreements (A$0.26m revenue in 1H FY26) |
| BOOSTER-Mag (legacy) | Agricultural crop-protection and yield product (magnesium-based) | Agriculture | Historically marketed; capitalised development costs still referenced in 1H FY26 intangibles note; current commercial status not disclosed | — |
Leilac segment (Leilac Limited)
| Offering | Description | Target customer | Status (Oct 2026) |
|---|---|---|---|
| Leilac kiln technology (cement/lime) | Indirectly heated calciner retrofitted to cement and lime plants. Process CO2 from limestone stays separate from combustion gases, so it can be captured without chemicals or extra process steps. "Hybrid" heating (fuels and/or electricity). Modular ~100,000 tpa CO2 module design. | Cement and lime producers | Pilot (Leilac-1, 25 ktpa, Lixhe); commercial projects in engineering |
| Leilac-1 | Pilot at Heidelberg Materials' Lixhe plant, Belgium; upgraded and retested in FY25 | R&D / demonstration | Operational pilot |
| Leilac-2 | ~100,000 tpa CO2 capture demonstration module (EU Horizon 2020 grant of ~€16m); JV with Heidelberg Materials at Ennigerloh | Heidelberg Materials | De-prioritised (29 Jun 2026): "remains delayed, with no line of sight to a timeline for completion" |
| Ambuja Cements commercial project | JDA to deploy Leilac at commercial scale at the Sanghi cement plant, Gujarat, India; all capex customer-funded on a "go" decision | Adani Group / Ambuja Cements | JDA executed 23 Jun 2026 |
| East Asia cement engineering study | Paid study (up to A$230k) to retrofit Leilac at a cement plant, capture ~100,000 tpa CO2 for local industrial use; capex customer-funded at FID | Confidential East Asian cement producer | Study runs Jul 2026 to 1H FY27 |
| Project ZETA | Electric calciner plus CCU for low-emissions lime in South Australia; pre-FEED completed Sep 2025; A$15m Australian Government grant awarded | Lime producers (SA) | Delayed pending matched funding |
| Zero-emissions lime for CDR (Frontier) | Near-zero-emissions lime for ocean alkalinity enhancement | Frontier buyers Google, Stripe, Shopify | Paid testing and TEA; completion due 1H FY27 |
| DAC application | Leilac kilns to regenerate sorbents for direct air capture | Previously Heirloom (Project Cypress); now open | Heirloom exclusivity removed Jun 2026 |
| US projects (Titan America, MLC) | DOE-selected cement and lime capture projects | US cement/lime producers | Paused; no DOE outcome |
Sustainable Processing segment
| Offering | Description | Partner / customer | Status |
|---|---|---|---|
| Zesty (Zero Emissions Steel TechnologY) | Flash hydrogen direct reduction of fine iron ore (H-DRI) in an electrically heated reactor; hydrogen used only as reductant and recycled; targets Pilbara-type fines without pelletising | Rio Tinto (JDA, >A$35m value); ARENA (up to A$44.9m) | Demonstration plant at Kwinana, WA in detailed design; ARENA milestone 1 paid (A$2m, Mar 2026); Rio first payment A$3m (Dec 2025, booked as SAFE financial liability); further A$5m prepaid tolling fee receivable as the project moves to FID; FID targeted FY27 |
| Lithium Mid-Stream technology | Electric calcination of spodumene concentrate into a higher-value "mid-stream" lithium phosphate/concentrate, reducing transport mass and emissions | PLS Group | Demo plant built (Dec 2025), commissioning from Apr 2026; Calix exited UJV for A$11.4m; PLS has a perpetual royalty-free licence for primary lithium processing; third-party royalties split 20:80 Calix:PLS |
| Alumina electrification | Calix kiln applied to calcination of alumina hydrate with electric heating | Norsk Hydro (Alunorte, Brazil) | Paid pilot-scale testing completed Jun 2026; testing and pre-FEED expected to yield >A$1.0m revenue |
| Paid material test campaigns | Customer feedstock testing in two electric calciners at Bacchus Marsh | Miners and processors | Ongoing |
| Legacy: advanced batteries | Nano-active battery materials (e.g., lithium manganese oxide) from flash calcination | Historic R&D | Not referenced as active in FY26 disclosures |
Financial Narrative
Sources: S&P Global Market Intelligence via StockAnalysis.com (income statement and cash flow updated 25 Aug 2026; balance sheet to 31 Dec 2025); Calix FY26 results release; 1H FY26 Interim Report. A$m unless stated. Fiscal years end 30 June. "Revenue" means product and services revenue, excluding other income (grants).
Income statement
Notes: - FY24 and FY25 pre-tax income includes "earnings from equity investments" (A$12.17m and A$15.07m) — non-cash gains on contribution to the PLS UJV.
-
FY26 pre-tax includes the A$30.3m loss on the UJV (impairment / sale).
-
Company-reported "revenue and other income": FY25 A$33.9m, FY26 A$39.2m (+16%).
-
Company-reported operating costs: FY25 A$39.5m, FY26 A$30.0m (-24%).
-
FY21 reference (S&P): revenue A$19.21m, gross profit A$5.05m, EBIT -A$5.13m, net income -A$7.49m.
Margins
Revenue CAGR:
-
FY22–FY26 (4 years): 18.2%
-
FY21–FY25: 10.0%
-
FY21–FY26 (5 years): (36.02/19.21)^(1/5) − 1 = 13.4%
Half-year progression (A$m): 1H FY25 revenue 13.51, 2H FY25 14.66, 1H FY26 16.32, 2H FY26 19.70 (derived: 36.02 − 16.32). 2H FY26 net loss attributable was approximately A$8.6m (derived: FY26 -51.03 less 1H -42.43), the lowest half-year loss in the recent series.
Commentary.
Inflection: FY26 is the first year that revenue growth (+28%) coincided with an absolute fall in opex (SG&A -14%, R&D -37%). EBIT loss improved by A$14.1m to -A$21.3m, and EBITDA margin halved from -97% to -43%.
Gross margin: Has stabilised around 39–40% after the FY24 peak (42.5%, helped by higher-margin Leilac services revenue). The mix shift to Magnesia (~37–39% segment gross margin) caps blended margin near 40%.
R&D intensity: Peaked at 88% of revenue in FY24 (Leilac-2 engineering, Zesty, lithium) and fell to 31% in FY26 as the company cut non-externally-funded projects.
Reported net loss: Distorted in both directions by UJV accounting: gains of A$12.2m in FY24 and A$15.1m in FY25, then a A$30.3m impairment in FY26. On "EBT excluding unusual items" (S&P), losses were -26.1 (FY24), -19.2 (FY25) and -21.4 (FY26). Underlying FY26 improvement is therefore smaller than the EBIT line suggests, because FY25 EBT benefited from the UJV gain.
Balance sheet
Latest balance sheet points (A$m):
Statutory intangibles of A$12.4m (FY25) include capitalised development costs. S&P splits these between "other intangibles" and "long-term deferred charges". Goodwill (A$3.6m) relates entirely to the 2019 IER acquisition. After the balance date, Calix received a further A$5.7m from PLS on 31 Jul 2026, so pro-forma cash was ~A$15.5m before any other movements.
Commentary. The balance sheet has contracted sharply. Total assets fell 35% in six months to A$72.2m at December 2025, mainly from the A$30.1m PP&E impairment of the Mid-Stream UJV. Net current assets turned negative (-A$2.3m) at 1H FY26, partly because of the A$3m Rio SAFE fee classed as a current financial liability and A$9.1m of deferred grant income. Financial debt is negligible: an asset-finance facility plus a USD500k IER working-capital line, being replaced by a Bank of America facility. The binding constraint is liquidity, not leverage. Cash fell from A$74.5m (FY23) to A$9.8m (FY26) despite a A$20m raise in Dec 2024.
Cash flow
Commentary. FY26 operating cash burn fell 60% to A$11.4m, and 1H FY26 burn was A$6.2m, down 65%. Management guides to cash-flow neutrality in calendar 2026, excluding the A$11.4m PLS proceeds. That depends on continued Magnesia growth, contracted grant milestones (ARENA, Australian Government), UK R&D tax incentives, and the second Rio Tinto JDA payment.
Ratios
Ratio notes: - FY26 ROE, ROIC, current ratio, debt/equity and asset turnover use the latest S&P TTM values (Dec 2025 balance sheet), because the full FY26 balance sheet was not available. FY26 ROA is likewise the S&P TTM figure.
-
ROIC for FY22–FY25 is an approximate analyst estimate (EBIT after nil tax ÷ equity + debt − cash); treat it as indicative.
-
Net debt/EBITDA: Calix is in net cash and EBITDA is negative, so the ratio is economically meaningless. The figures shown are net cash ÷ |EBITDA| (years of EBITDA burn covered by net cash). The FY26 figure is an estimate: ~A$8.8m net cash at Dec 2025 ÷ A$15.56m.
-
Interest coverage is negative in every year (EBIT loss; S&P TTM -106x).
-
Cash conversion cycle (DSO + DIO − DPO on year-end balances) was derived for FY24 (49 days) and FY25 (-16 days) only. Other years are shown as 0 placeholders: not computed / not disclosed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Key assets |
|---|---|---|
Magnesia | Magnesium oxide and hydroxide for wastewater (ACTI-Mag / MHL), biogas, aquaculture (AQUA-Cal+) and related uses; formerly the "Water" line of business | Bacchus Marsh commercial calciner (up to 25 ktpa MgO); Myrtle Springs SA magnesite mine; hydration plants in Victoria and Queensland; six North American manufacturing facilities (IER) |
Leilac (CO2 mitigation) | Cement and lime carbon capture and electrification; zero-emissions lime for CDR; DAC applications. Held via Leilac Limited (formerly LEILAC Group / Calix (Europe) Ltd), in which Carbon Direct holds a minority interest (6.98% at 2021 entry) | Leilac-1 pilot, Lixhe, Belgium; Leilac-2 JV (Ennigerloh, de-prioritised) |
Sustainable Processing (SusPro) | Zesty green iron; lithium mid-stream (until Apr 2026 restructure); alumina (Hydro); other critical minerals; paid material testing | Two electric test calciners at Bacchus Marsh; former 41% share of the Mid-Stream UJV with PLS |
Corporate | Group functions, R&D platform, finance, administration | Sydney HQ; Calix Technology Centre laboratory |
Revenue by Segment
| Segment (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Magnesia revenue | 20.9 | 24.3 | 34.0 |
Leilac revenue | 3.2 | 3.8 | 1.0 |
SusPro revenue | 0.1 | 0.1 | 1.0 |
Total product and services revenue | 24.2 | 28.2 | 36.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Magnesia YoY growth (%) | 0 | 16 | 40 |
Magnesia share of product and services revenue (%) | 86 | 86 | 94 |
Group product and services revenue growth (%) | 30 | 17 | 28 |
Results by Segment
| Metric (AUD Mn) | 1H FY25 | 1H FY26 |
|---|---|---|
Magnesia revenue | 10.65 | 15.75 |
Magnesia gross profit | 4.05 | 6.17 |
Magnesia net profit (loss) | -1.87 | 0.64 |
Leilac revenue | 2.86 | 0.00 |
Leilac gross profit | 0.81 | -0.02 |
Leilac net profit (loss) | -9.27 | -5.16 |
SusPro revenue | 0.00 | 0.56 |
SusPro gross profit | 0.00 | 0.54 |
SusPro net profit (loss) | 6.79 | -30.63 |
Corporate net profit (loss) | -8.38 | -7.64 |
Group net profit (loss) | -12.74 | -42.79 |
Margin (%)
| Margin (%) | 1H FY25 | 1H FY26 |
|---|---|---|
Magnesia gross margin | 38.0 | 39.1 |
Magnesia segment net margin | -17.6 | 4.1 |
Group gross margin | 36.0 | 41.0 |
Income Statement and Margin Analysis (%)
| Metric (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue | 18.47 | 18.60 | 24.19 | 28.17 | 36.02 |
Revenue growth (%) | -3.86 | 0.72 | 30.05 | 16.46 | 27.85 |
Cost of revenue | 13.27 | 12.40 | 13.91 | 17.52 | 21.79 |
Gross profit | 5.20 | 6.20 | 10.29 | 10.65 | 14.24 |
SG&A | 12.57 | 17.15 | 20.55 | 21.78 | 18.73 |
R&D expense | 7.10 | 14.53 | 21.38 | 17.82 | 11.27 |
Operating income (EBIT) | -16.68 | -23.38 | -38.72 | -35.39 | -21.31 |
EBITDA (S&P) | -12.94 | -17.87 | -32.06 | -27.36 | -15.56 |
Pre-tax income | -16.77 | -23.49 | -26.29 | -20.22 | -51.69 |
Net income attributable | -16.34 | -23.19 | -25.26 | -19.17 | -51.03 |
EPS basic (AUD) | -0.10 | -0.13 | -0.14 | -0.10 | -0.24 |
EPS diluted (AUD) | -0.10 | -0.13 | -0.14 | -0.10 | -0.24 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
Weighted shares basic (m) | 160 | 174 | 182 | 200 | 215 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin (%) (Annual)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin | 28.2 | 33.3 | 42.5 | 37.8 | 39.5 |
Operating (EBIT) margin | -90.3 | -125.7 | -160.1 | -125.6 | -59.2 |
EBITDA margin | -70.1 | -96.1 | -132.5 | -97.1 | -43.2 |
Net margin | -88.5 | -124.7 | -104.4 | -68.1 | -141.7 |
R&D as % of revenue | 38.4 | 78.1 | 88.4 | 63.3 | 31.3 |
Balance Sheet and Share Count (m)
| Metric (AUD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | 51.62 | 61.21 | 127.51 | 112.40 | 110.38 |
Cash and equivalents | 15.13 | 24.98 | 74.47 | 42.96 | 22.98 |
Short-term debt incl current leases | 0.63 | 1.15 | 0.68 | 1.54 | 0.99 |
Long-term debt incl leases | 0.65 | 0.34 | 0.65 | 1.72 | 1.64 |
Total debt (incl leases) | 1.29 | 1.47 | 1.32 | 3.26 | 2.63 |
Net debt (negative = net cash) | -14.16 | -23.71 | -73.46 | -40.00 | -20.62 |
Total equity | 38.15 | 44.80 | 104.96 | 84.00 | 87.55 |
Goodwill | 3.64 | 3.64 | 3.64 | 3.64 | 3.64 |
Other intangibles (S&P classification) | 4.76 | 4.74 | 4.70 | 4.64 | 4.42 |
PP&E | 15.32 | 19.24 | 25.39 | 43.10 | 60.33 |
Current assets | 27.02 | 31.61 | 89.11 | 52.72 | 31.88 |
Current liabilities | 11.71 | 15.13 | 20.93 | 25.72 | 20.37 |
Working capital | 15.31 | 16.48 | 68.18 | 27.00 | 11.52 |
Deferred revenue (mainly grants) | 6.51 | 9.35 | 13.26 | 10.10 | 9.64 |
Shares outstanding (m) | 158.55 | 161.50 | 181.18 | 181.92 | 214.75 |
Financial Analysis
| Item | 30 Jun 2025 | 31 Dec 2025 | 30 Jun 2026 |
|---|---|---|---|
Cash | 22.98 | 11.80 | 9.80 |
Total assets | 110.38 | 72.23 | — |
PP&E | 57.74 | 31.84 | — |
Intangibles (statutory) | 12.41 | 10.42 | — |
Goodwill | 3.64 | 3.64 | — |
Borrowings | 0.14 | 0.17 | — |
Rio Tinto SAFE liability | 0.00 | 3.00 | — |
Total equity | 87.55 | 45.90 | — |
Net current assets | 11.52 | -2.33 | — |
“—” = not publicly disclosed.
Cash Flow
| Metric (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | -3.74 | -17.26 | -13.68 | -28.67 | -11.38 |
Capital expenditure (S&P, incl UJV share) | -7.44 | -9.86 | -15.12 | -10.28 | -8.33 |
Free cash flow | -11.18 | -27.11 | -28.79 | -38.95 | -19.70 |
Equity issued | 0.81 | 81.59 | 0 | 22.09 | 0 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Net change in cash | 9.85 | 49.48 | -31.51 | -19.98 | -13.21 |
Stock-based compensation | 0.31 | 2.74 | 5.13 | 2.66 | 2.06 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) — on average equity | -39.4 | -31.0 | -26.7 | -22.3 | -72.9 |
ROA (%) — on average assets | -29.0 | -24.6 | -21.1 | -17.2 | -17.2 |
ROIC (%) — S&P | -35.0 | -28.0 | -30.0 | -25.0 | -22.7 |
Current ratio (x) | 2.09 | 4.26 | 2.05 | 1.57 | 0.90 |
Debt / equity (x, incl leases) | 0.03 | 0.01 | 0.04 | 0.03 | 0.07 |
Net debt / EBITDA (x) | 1.83 | 4.11 | 1.25 | 0.75 | 0.57 |
Asset turnover (x) | 0.33 | 0.20 | 0.20 | 0.25 | 0.33 |
Cash conversion cycle (days, derived) | 0 | 0 | 49 | -16 | 0 |
Revenue by Region
| Region (AUD Mn) | 1H FY25 | 1H FY26 |
|---|---|---|
APAC including Australia | 2.17 | 4.61 |
EMEA | 0.00 | 0.00 |
Americas | 11.35 | 11.70 |
Total | 13.51 | 16.32 |
Region growth and share (%)
| Region growth and share (%) | 1H FY25 | 1H FY26 |
|---|---|---|
APAC YoY growth (%) | 0 | 112.8 |
Americas YoY growth (%) | 0 | 3.2 |
APAC share of revenue (%) | 16.0 | 28.3 |
Americas share of revenue (%) | 84.0 | 71.7 |
Segment Overview — Magnesia
| Segment | APAC | EMEA | Americas | Total |
|---|---|---|---|---|
Magnesia | 4.45 | 0.00 | 11.31 | 15.75 |
Leilac | 0.00 | 0.00 | 0.00 | 0.00 |
SusPro | 0.17 | 0.00 | 0.40 | 0.56 |
Total | 4.61 | 0.00 | 11.70 | 16.32 |
Segment × geography (1H FY25, AUD Mn) | APAC | EMEA | Americas | Total |
Magnesia | 2.01 | 0.00 | 8.65 | 10.65 |
Leilac | 0.16 | 0.00 | 2.70 | 2.86 |
SusPro | 0.00 | 0.00 | 0.00 | 0.00 |
Total | 2.17 | 0.00 | 11.35 | 13.51 |
Capital Markets
| Measure | Value | Source / note |
|---|---|---|
Last price (8 Oct 2026) | A$0.225 | StockAnalysis |
52-week high | ~A$1.77 | SmallCaps (early 2026) |
52-week low | ~A$0.225 (current) | Derived |
Price at FY26 results (26 Aug 2026) | A$0.30 at release; ~A$0.23 after | InvestSMART |
1-year change (from ~A$0.47–0.49, Oct 2025) | approx -53% | InvestSMART release prices |
Beta (5Y) | 0.75 | S&P |
Average daily volume (20-day, Aug 2026) | ~345,000 shares | S&P |
Share Price
| Price point (AUD) | Nov 2025 | Dec 2025 | Feb 2026 | Mar 2026 | Jun 2026 | Aug 2026 | Oct 2026 |
|---|---|---|---|---|---|---|---|
Share price at key releases | 0.465 | 0.515 | 1.59 | 0.75 | 0.425 | 0.30 | 0.225 |
Valuation Multiples
| Multiple | Calix (approx, 8 Oct 2026) | Basis |
|---|---|---|
Market cap | A$48.6m | 215.8m × A$0.225 |
Enterprise value | ~A$36m | Market cap − ~A$15.5m pro-forma cash (A$9.8m + A$5.7m PLS) + ~A$3m debt and leases (estimate) |
EV / Sales (FY26) | ~1.0x | A$36m ÷ A$36.0m |
P / Sales (FY26) | ~1.35x | A$48.6m ÷ A$36.0m |
P / E | n/m (loss-making) | — |
EV / EBITDA | n/m (negative EBITDA) | — |
P / B | ~1.06x on 1H FY26 book (A$45.9m); FY26 book not disclosed in sources reviewed | — |
Capital Markets — Dividend policy
| Item | Detail |
|---|---|
Dividend policy | No dividends paid as a listed company; none expected while loss-making. (InvestSMART shows legacy 2004–2005 dividends for the CXL code, likely from a prior entity on that ticker.) |
Buybacks | None authorised |
Credit ratings (Moody's / S&P / Fitch) | None — unrated |
Debt maturity profile | Negligible: asset-finance facilities (A$0.16m current), lease liabilities (~A$3.1m, current A$1.0m), Bank of America facility (size not disclosed) |
Equity raised (AUD Mn)
| Equity raised (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Common stock issued (cash) | 0.81 | 81.59 | 0 | 22.09 | 0 |
Analyst Conclusions
Management guidance
-
Cash-flow neutral in calendar 2026, excluding the A$11.4m PLS proceeds.
-
Continued Magnesia revenue and gross-profit growth.
-
Progress paid test campaigns in SusPro.
-
Advance financing and FID for the Zesty demo.
-
Commercialise Leilac through capital-light, customer-funded projects.
-
A$3m of PLS proceeds reinvested in Zesty.
Consensus expectations
S&P shows a 3-year revenue growth forecast of ~24.5% a year. No published EBITDA or EPS consensus was identified. Coverage is thin (two brokers) and targets appear stale.
Bull case
-
Magnesia becomes a scaled, cash-generative core. FY26 revenue was A$34.0m (+40%) with the up-to-A$10m-a-year US contract only partly reflected. Annualising 2H FY26 group revenue (~A$19.7m per half) implies ~A$39–45m in FY27. At ~40% gross margin and a A$30m opex base trending down, group EBITDA breakeven is within reach.
-
Customer-funded Leilac deployments re-rate the platform. A "go" decision at Ambuja's Sanghi plant or the East Asian plant would deliver Leilac's first commercial cement plant without Calix capital, monetised through engineering fees and royalties (Calix keeps 30% of Leilac royalties).
-
Zesty FID crystallises value. Rio Tinto (>A$35m) and ARENA (A$42.9m remaining) would fund a green-iron demo with a mining major. Project-level equity (SAFE conversion) could reveal a valuation well above the current ~A$36m group EV.
Bear case
-
Liquidity squeeze forces a dilutive raise. Cash was A$9.8m at FY26 (~A$15.5m pro-forma). Neutrality depends on milestone-linked inflows (Rio's second payment, ARENA, UK R&D incentives), and any slippage means raising equity at a depressed price.
-
Repeated failure to reach commercial scale. Leilac has been in pilot since 2019. Leilac-2 is shelved, ZETA is unfunded and the US projects are paused. The lithium exit crystallised a A$30.2m loss, which suggests the platform's economics are hard to prove at scale.
-
Magnesia alone does not justify the cost base. Even a profitable A$40m magnesia business, valued as a niche specialty chemical, may not support a structure carrying ~A$15m of corporate and R&D cost unless licensing revenue materialises.
Key catalysts and monitorables (next 12 months)
| Catalyst | Expected timing | Watch for |
|---|---|---|
| FY26 Annual Report and 2026 AGM | Oct–Nov 2026 | Remuneration vote, FY26 balance sheet, segment detail, going-concern wording |
| Magnesia quarterly run-rate and US contract ramp | Ongoing; 1H FY27 results Feb 2027 | Revenue per half above A$20m; gross margin at or above 40% |
| CY2026 cash-flow neutrality | Dec 2026 / Feb 2027 report | Cash at 31 Dec 2026 versus ~A$15.5m pro-forma |
| Zesty financing and FID | FY27 | Third-party equity, Rio second payment, ARENA milestones |
| East Asia engineering study completion | 1H FY27 | Progression to FEED or FID |
| Ambuja "go" decision | FY27 or later | Commercial terms, royalty structure |
| Frontier CDR phase completion | 1H FY27 | Follow-on offtake or contracts |
| Hydro pre-FEED | FY27 | Path to licence |
| Leilac-2 consortium alternative plan | Uncertain | Restructuring or termination; grant implications |
| Capital raising | Any time | Size, price, investor support (AustralianSuper, Thorney/TIGA) |
Concluding analyst verdict
Calix enters FY27 as a smaller, more disciplined and far less valued company than it was eighteen months ago. FY26 confirmed two things.
First, the Magnesia business is real. Revenue rose 40% to A$34.0m at a ~37–40% gross margin, the segment is now profitable, and it has a contracted growth leg in the US. That business alone plausibly supports a meaningful part of today's ~A$49m market capitalisation.
Second, the strategy of funding first-of-a-kind decarbonisation plants on Calix's own balance sheet has failed financially, even where execution was competent. The lithium Mid-Stream plant was built on budget, yet Calix exited at a A$30.2m impairment. Leilac-2 is shelved after the Hanover relocation and European demand weakness, and US federal funding has disappeared.
Management's pivot to a capital-light, customer-funded model is the correct response, and it is supported by unusually strong counterparties: Rio Tinto, Norsk Hydro, Adani/Ambuja and Frontier's corporate buyers. Cost cuts are real: opex fell 24%, cash capex 80% and operating burn 60%.
The pivot does have a price. Calix now depends on partners' timetables and milestone-based payments to stay solvent, with only ~A$15.5m of pro-forma liquidity. The market is pricing this as a distressed option: EV of about 1x sales, roughly at book value, with negligible credit given to Leilac or Zesty.
Our view is that CXL is a high-risk, special-situation holding. Its value rests on (1) achieving the CY2026 cash-neutral target without a deeply dilutive raise and (2) at least one customer-funded commercial decision (Ambuja, East Asia or a Zesty FID) within 12–18 months. Delivery on both would make today's valuation look anomalously low against the Magnesia earnings stream alone. A missed cash target or a stalled Zesty financing would likely force equity issuance at or below current levels. Position sizing should reflect binary outcomes, and investors should track half-year cash balances above all other metrics.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background / education | Independence |
|---|---|---|---|---|
Alison (Catriona) Deans | Non-Executive Chair | Director Mar 2023; Chair from 1 Oct 2024 | Former CEO of eBay ANZ, eCorp, Hoyts Cinemas and netus; ex-McKinsey; Chair of Cochlear; NED of Ramsay Health Care; former NED of Westpac and IAG; Investment Committee, Main Sequence Ventures | Independent |
Dr Phil Hodgson | Managing Director & CEO | CEO since Jan 2013 | BE, PhD; prior commercial and technical roles at Shell | Executive |
Helen Fisher | Non-Executive Director | — | — | Independent (presumed) |
Dr Sarah Ryan | Non-Executive Director | 2024 (casual vacancy; elected at 2024 AGM) | — | Independent (presumed) |
Peter Dixon | Non-Executive Director | 2024 (casual vacancy; elected at 2024 AGM) | — | Independent (presumed) |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Title | Notes |
|---|---|---|
Dr Phil Hodgson | MD & CEO | CEO since 2013; holds ~2.3% of shares (~4.9m) |
Darren Charles | CFO & Company Secretary | B Com, FCPA |
Daniel Rennie | CEO, Leilac Group | Leads Leilac since its 2021 stand-alone structure |
Dr Matt Boot-Handford | Chief Scientist | Succeeded Sceats in the scientific lead role |
Dr Mark Sceats | Co-Founder & Emeritus Chief Scientist | ~3.6% holder |
Simon Thomsen | Chief Technology Officer | — |
Michelle Bennett | Chief Engineering & Projects Officer | — |
Helen Comerford | Chief People & Culture Officer | — |
Dr Doug Kelley | GM Water (North America) & President, IER | — |
Andrew Okely | GM Commercial | — |
Vincent Nguyen | GM Operations | — |
Christineh Grigorian | Investor Relations Manager | — |
Directors' Remuneration
| Person | Year | Salary (AUD K) | Variable / equity (AUD K) | Total (AUD K) | Source |
|---|---|---|---|---|---|
Phil Hodgson (CEO) | FY25 | 463 | 110 | 573 | Simply Wall St (from FY25 remuneration report) |
Phil Hodgson | Earlier (Yahoo) | — | — | 520 | Yahoo Finance |
Darren Charles (CFO) | Earlier (Yahoo) | — | — | 380 | Yahoo Finance |
Daniel Rennie (Leilac CEO) | Earlier (Yahoo) | — | — | 392 | Yahoo Finance |
Doug Kelley (IER) | Earlier (Yahoo) | — | — | 390 | Yahoo Finance |
Board & Management Changes
| Date | Change |
|---|---|
30 Sep 2024 | Peter Turnbull AM retires as Chair (Chair since the 2018 listing; associated with Calix since about 2009) |
1 Oct 2024 | Alison Deans becomes Chair |
| 2024 | Peter Dixon and Dr Sarah Ryan appointed to fill casual vacancies |
FY25 | Streamlining of teams under the cost-reduction programme |
Major Shareholders
| Holder | Shares (m) | Stake (%) | Type | Source / date |
|---|---|---|---|---|
AustralianSuper Pty Ltd | 37.43 | 17.4 | Institution (superannuation) | Simply Wall St (2025–26) |
TIGA Trading Pty Ltd (Thorney group) | 17.32 | 8.1 | Institution / family office | Simply Wall St |
Nicholas Merriman | 10.97 | 5.1 | Individual | Simply Wall St |
Mark Sceats (co-founder) | 7.76 | 3.6 | Insider | Simply Wall St |
Paul Crowther | 5.39 | 2.5 | Individual | Simply Wall St |
Phil Hodgson (CEO) | 4.92 | 2.3 | Insider | Simply Wall St |
Thorney Technologies Ltd | 4.69 | 2.2 | Institution (listed investment co) | Simply Wall St |
Handelsbanken Asset Management | 4.09 | 1.9 | Institution | Simply Wall St |
Fidelity International | ~1.9 | 0.9 | Institution | Simply Wall St |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Relative positioning vs Calix |
|---|---|---|---|
Magnesia (US wastewater Mg(OH)2) | Martin Marietta Magnesia Specialties (US) | Division of a large-cap aggregates company | Larger, integrated US magnesia producer; scale advantage |
Magnesia | Premier Magnesia (US) | Private | Established US Mg(OH)2 slurry supplier; direct head-to-head |
Magnesia | Huber Engineered Materials / other Mg(OH)2 suppliers | Private / large chemical | Broad product range |
Magnesia | Caustic soda and lime suppliers (e.g., Olin, OxyChem, Carmeuse, Lhoist) | Substitute chemistries | Calix sells Mg(OH)2 as a safer, buffering alternative to caustic |
Magnesia (Australia) | Queensland Magnesia (QMAG; RHI Magnesita group) | Global refractory major | Upstream magnesia supplier; competes in some industrial grades |
Leilac (cement capture) | SLB Capturi (ex-Aker Carbon Capture) | Amine capture | Commercial-scale reference at Heidelberg Brevik (Norway); higher energy penalty but proven |
Leilac | Mitsubishi Heavy Industries (KM CDR) | Amine capture | Large-cap, global references in power and industry |
Leilac | thyssenkrupp Polysius (oxyfuel / "pure oxyfuel") | Oxyfuel kilns | Direct alternative for kiln process CO2; OEM incumbency |
Leilac | FLSmidth Cement (now Pacific Avenue Capital) | Kiln OEM | Incumbent kiln supplier; electrification R&D |
Leilac | Air Liquide (Cryocap), Linde | Cryogenic / gas-separation capture | Industrial-gas majors with project-delivery capacity |
Leilac / electrification | Coolbrook (RotoDynamic Heater) | Electrified high-temperature heat | Competes on electrification thesis |
CDR lime / DAC | Origen (zero-emission lime), Heirloom (now non-exclusive), Climeworks | CDR developers | Compete for Frontier-type offtake capital |
Zesty (green iron) | Midrex (Kobe Steel), Energiron (Tenova / Danieli), HYFOR (Primetals), HYBRIT | H-DRI / fines reduction | Midrex and Energiron dominate DRI; HYFOR targets fines like Zesty |
Zesty | Boston Metal, Electra | Electrochemical iron | Alternative green-iron routes |
Alumina electrification | Alcoa (mechanical vapour recompression, electric calcination R&D), Rio Tinto internal programmes | Incumbent producers | Producers may build in-house solutions |
Lithium mid-stream | Conventional rotary-kiln spodumene conversion (Chinese converters) | Incumbent process | Calix offers on-site electric calcination |
Peer Comparison FY2026
| Metric | Calix (FY26) | SLB Capturi | Midrex (Kobe Steel) |
|---|---|---|---|
Revenue | A$36.0m | — | — |
Revenue growth | +28% | — | — |
Gross margin | 39.5% | — | — |
R&D intensity | 31% of revenue | — | — |
Commercial reference plants in core decarbonisation tech | 0 (pilot only) | ≥1 cement (Brevik) | ~100 DRI modules (gas-based) |
“—” = not publicly disclosed.
Recent Developments
Layoffs: * FY25 headcount reductions (redundancies A$1.0m in 1H FY25; A$0.36m in 1H FY26).



